Lonely killers: Effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions

mAbs

Volumn 3, Issue 6, 2011, Pages

  Fernández Marrero, Yuniel ^a   López Requena, Alejandro ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cell death; Cytotoxicity; Membrane lesion; Necrosis; Therapeutic antibody

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; COMPLEMENT; FC RECEPTOR; GANGLIOSIDE GM3; INFLIXIMAB; IPILIMUMAB; ITOLIZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14F7; MONOCLONAL ANTIBODY AD5 10; MONOCLONAL ANTIBODY BR96; MONOCLONAL ANTIBODY P3; MONOCLONAL ANTIBODY RAV12; NIMOTUZUMAB; OTELIXIZUMAB; RITUXIMAB; TEPLIZUMAB; TRASTUZUMAB; TUMOR ASSOCIATED N GLYCOLYL GM3 GANGLIOSIDE; UNCLASSIFIED DRUG; CANCER ANTIBODY; DRUG DERIVATIVE; TUMOR ANTIGEN;

ADENOCARCINOMA; APOPTOSIS; BINDING AFFINITY; CELL MEMBRANE; CYTOTOXICITY; DRUG ERUPTION; DRUG MECHANISM; EFFECTOR CELL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; MEMBRANE DAMAGE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; IMMUNOLOGY; MOUSE; NEOPLASM; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CELL MEMBRANE; G(M3) GANGLIOSIDE; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS;

EID: 81255197760     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.6.17770     Document Type: Review

References (96)

1. Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 2010; 16:11-20; PMID:20028761; DOI:10.1158/1078-0432.CCR-09-2345.
2. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; DOI:10.1038/nri2761.
3. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; DOI:10.1038/nri2744.
4. Scolnik PA. mAbs: a business perspective. MAbs 2009; 1:179-84; PMID:20061824; DOI:10.4161/mabs.1.2.7736.
5. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76-99; PMID:21051951; DOI:10.4161/mabs.3.1.13895.
6. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol 2009; 27:129-39; PMID:19204689; DOI:10.1038/nbt0209-129.
7. Carballido E, Fishman M. Sipuleucel-T: Prototype for development of anti-tumor vaccines. Curr Oncol Rep 2011; 13:112-9; PMID:21243538; DOI:10.1007/s11912-011-0152-5.
8. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011; 239:27-44; PMID:21198663; DOI:10.1111/j.1600-065X.2010.00979.x.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; DOI:10.1016/j.cell.2011.02.013.
10. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; DOI:10.1038/nri2747.
11. Lopez-Requena A, Burrone OR. Anti-idiotypic antibodies and "tumor-only" antigens: an update. Open Immunol J 2009; 2:1-8; DOI:10.2174/1874226200902010001.
12. Hinojosa LE, Hernandez T, de Acosta CM, Montero E, Perez R, Lopez-Requena A. Construction of a recombinant non-mitogenic anti-human CD3 antibody. Hybridoma (Larchmt) 2010; 29:115-24; PMID:20443703; DOI:10.1089/hyb.2009.0042.
13. Alonso R, Huerta V, de Leon J, Piedra P, Puchades Y, Guirola O, et al. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. Hybridoma (Larchmt) 2008; 27:291-301; PMID:18707547; DOI:10.1089/hyb.2008.0007.
14. Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, et al. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010; 2010:814397. PMID:21048926; DOI:10.1155/2010/814397.
15. Liu XY, Pop LM, Vitetta ES. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008; 222:9-27; PMID:18363992; DOI:10.1111/j.1600-065X. 2008.00601.x.
16. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635-42; PMID:15226177; DOI:10.1182/blood-2004-03-1110.
17. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47:115-23; PMID:20350658; DOI:10.1053/j.seminhematol.2010.01.011.
18. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16:3-11; PMID:18846107; DOI:10.1038/cdd.2008.150.
19. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007; 179:2832-43; PMID:17709497.
20. Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, et al. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 2008; 57:247-63; PMID:17657488; DOI:10.1007/s00262-007-0371-7.
21. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 2009; 58:915-30; PMID:18941743; DOI:10.1007/s00262-008-0607-1.
22. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, et al. Allergo Oncology: the role of IgE-mediated allergy in cancer. Allergy 2008; 63:1255-66; PMID:18671772; DOI:10.1111/j.1398-9995.2008.01768.x.
23. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004; 4:592-603; PMID:15286739; DOI:10.1038/nrc1412.
24. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2:589-98; PMID:11483992; DOI:10.1038/35085008.
25. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10:221-37; PMID:21358741; DOI:10.1038/nrd3373.
26. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity and immunoescape. J Clin Oncol 2010; 28:4390-9; PMID:20697078; DOI:10.1200/JCO.2009. 27.6360.
27. Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 2009; 1:222-9; PMID:20065642; DOI:10.4161/mabs.1.3.8292.
28. Alpizar YA, Chain B, Collins MK, Greenwood J, Katz D, Stauss HJ, et al. Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother 2011; 60:1127-35; PMID: 21479639; DOI: 10.1007/s00262-011-0985-7.
29. Perez R, Moreno E, Garrido G, Crombet T. EGFR-targeting as a biological therapy: understanding Nimotuzumab's clinical effects. Cancers 2011; 3:2014-31; DOI:10.3390/cancers3022014.
30. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 2009; 113:3809-12; PMID:19196657; DOI:10.1182/blood-2008-10-185280.
31. Garrido G, Sanchez B, Rodriguez HM, Lorenzano P, Alonso D, Fernandez LE. 7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies. Hybrid Hybridomics 2004; 23:168-75; PMID:15312307; DOI:10.1089/1536859041224280.
32. Garrido G, Lorenzano P, Sanchez B, Beausoleil I, Alonso DF, Perez R, et al. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immunother 2007; 56:1701-10; PMID:17415565; DOI:10.1007/s00262-007-0313-4.
33. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407:784-8; PMID:11048729; DOI:10.1038/35037722.
34. Matzinger P. An innate sense of danger. Ann NY Acad Sci 2002; 961:341-2; PMID:12081934; DOI:10.1111/j.1749-6632.2002.tb03118.x.
35. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8:279-89; PMID:18340345; DOI:10.1038/nri2215.
36. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9:353-63; PMID:19365408; DOI:10.1038/nri2545.
37. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004; 84:131-79; PMID:15246252; DOI:10.1016/S0065-2776(04)84004-5.
38. Hellström I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990; 50:2183-90; PMID:1690595.
39. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 2000; 6:78-81; PMID:11069223.
40. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 2000; 18:2282-92; PMID:10829049.
41. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002; 8:3092-9; PMID:12374676.
42. Garrigues J, Garrigues U, Hellstrom I, Hellstrom KE. Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am J Pathol 1993; 142:607-22; PMID:8434651.
43. Matsuoka S, Asano Y, Sano K, Kishimoto H, Yamashita I, Yorifuji H, et al. A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement. J Exp Med 1995; 181:2007-15; PMID:7759995; DOI:10.1084/jem.181.6.2007.
44. Bhat NM, Bieber MM, Stevenson FK, Teng NN. Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies. Clin Exp Immunol 1996; 105:183-90; PMID:8697629; DOI:10.1046/j.1365-2249.1996.d01- 733.x.
45. Bhat NM, Bieber MM, Hsu FJ, Chapman CJ, Spellerberg M, Stevenson FK, et al. Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies, II. Clin Exp Immunol 1997; 108:151-9; PMID:9097924; DOI:10.1046/j.1365-2249.1997.d01-976.x.
46. Zhang C, Xu Y, Gu J, Schlossman SF. A cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosis. Proc Natl Acad Sci USA 1998; 95:6290-5; PMID:9600958; DOI:10.1073/pnas.95.11.6290.
47. Ma F, Zhang C, Prasad KV, Freeman GJ, Schlossman SF. Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death. Proc Natl Acad Sci USA 2001; 98:9778-83; PMID:11481458; DOI:10.1073/pnas.171322898.
48. Loo D, Pryer N, Young P, Liang T, Coberly S, King KL, et al. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther 2007; 6:856-65; PMID:17363480; DOI:10.1158/1535-7163.MCT- 06-0581.
49. Coberly SK, Chen FZ, Armanini MP, Chen Y, Young PF, Mather JP, et al. The RAV12 monoclonal antibody recognizes the N-linked glycotope RAAG12: expression in human normal and tumor tissues. Arch Pathol Lab Med 2009; 133:1403-12; PMID:19722746.
50. Burris HA, 3rd, Rosen LS, Rocha-Lima CM, Marshall J, Jones S, Cohen RB, et al. Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin Cancer Res 2010; 16:1673-81; PMID:20179219; DOI:10.1158/1078-0432.CCR-09-2263.
51. Choo AB, Tan HL, Ang SN, Fong WJ, Chin A, Lo J, et al. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin- like protein-1. Stem Cells 2008; 26:1454-63; PMID:18356574; DOI:10.1634/stemcells.2007-0576.
52. Tan HL, Fong WJ, Lee EH, Yap M, Choo A. mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem Cells 2009; 27:1792-801; PMID:19544435; DOI:10.1002/stem.109.
53. Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000; 19:241-7; PMID:10952412; DOI:10.1089/02724570050109639.
54. Varki A. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. Proc Natl Acad Sci USA 2010; 107:8939-46; PMID:20445087; DOI:10.1073/pnas.0914634107.
55. Oliva JP, Valdes Z, Casaco A, Pimentel G, Gonzalez J, Alvarez I, et al. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res Treat 2006; 96:115-21; PMID:16322892; DOI:10.1007/s10549-005-9064-0.
56. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res 1996; 56:5165-71; PMID:8912852.
57. Mulens V, de la Torre A, Marinello P, Rodriguez R, Cardoso J, Diaz R, et al. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum Vaccin 2010; In press; PMID:20855939.
58. Alfonso M, Diaz A, Hernandez AM, Perez A, Rodriguez E, Bitton R, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002; 168:2523-9; PMID:11859147.
59. Díaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 2003; 107:80-9; PMID:12763476; DOI:10.1016/S1521-6616(03)00036-6.
60. Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, et al. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 2006; 29:215-23; PMID:16531822; DOI:10.1097/01.cji.0000188502.11348.34.
61. Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007; 6:145-50; PMID:17218777; DOI:10.4161/cbt.6.2.3574.
62. Alfonso S, Diaz RM, de la Torre A, Santiesteban E, Aguirre F, Perez K, et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 2007; 6:1847-52; PMID:18075301; DOI:10.4161/cbt.6.12.5000.
63. Hernández AM, Toledo D, Martinez D, Grinan T, Brito V, Macias A, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008; 181:6625-34; PMID:18941253.
64. Krengel U, Olsson LL, Martinez C, Talavera A, Rojas G, Mier E, et al. Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. J Biol Chem 2004; 279:5597-603; PMID:14627696; DOI:10.1074/jbc.M311693200.
65. Carr A, Mesa C, del Carmen Arango M, Vazquez AM, Fernandez LE. In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybrid Hybridomics 2002; 21:463-8; PMID:12573110; DOI:10.1089/153685902321043990.
66. Roque-Navarro L, Chakrabandhu K, de Leon J, Rodriguez S, Toledo C, Carr A, et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 2008; 7:2033-41; PMID:18645013; DOI:10.1158/1535- 7163.MCT-08-0222.
67. Mateo C, Lombardero J, Moreno E, Morales A, Bombino G, Coloma J, et al. Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. Hybridoma 2000; 19:463-71; PMID:11152398; DOI:10.1089/027245700750053959.
68. Fernandez-Marrero Y, Roque-Navarro L, Hernandez T, Dorvignit D, Molina-Perez M, Gonzalez A, et al. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated- glycoconjugates. Immunobiology 2011; In press.
69. Majno G, Joris I. Apoptosis, oncosis and necrosis. An overview of cell death. Am J Pathol 1995; 146:3-15; PMID:7856735.
70. Matsuoka S, Tsurui H, Abe M, Terashima K, Nakamura K, Hamano Y, et al. A monoclonal antibody to the alpha2 domain of murine major histocompatibility complex class I that specifically kills activated lymphocytes and blocks liver damage in the concanavalin A hepatitis model. J Exp Med 2003; 198:497-503; PMID:12885869; DOI:10.1084/jem.20021301.
71. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3:586-99; PMID:12154370; DOI:10.1038/nrm882.
72. Takeda T, McQuistan T, Orlando RA, Farquhar MG. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest 2001; 108:289-301; PMID:11457882.
73. Pal SK, Pegram M. Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 2005; 16:483-94; PMID:15846113; DOI:10.1097/00001813-200506000-00003.
74. Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69:5851-9; PMID:19584289; DOI:10.1158/0008-5472.CAN-08-4518.
75. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646-54; PMID:15117987; DOI:10.1200/JCO.2004.03.089.
76. Ramos TC, Figueredo J, Catala M, Gonzalez S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006; 5:375-9; PMID:16575203; DOI:10.4161/cbt.5.4.2522.
77. Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, et al. Nimotuzumab plus radiotherapy for unresectable squamous- cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9:343-9; PMID:20448462; DOI:10.4161/cbt.9.5.10981.
78. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11:373-82; PMID:21150278; DOI:10.4161/cbt.11.4.14097.
79. Rodríguez M, Roque-Navarro L, Lopez-Requena A, Moreno E, Mateo de Acosta C, Perez R, et al. Insights into the immunogenetic basis of two ganglioside- associated idiotypic networks. Immunobiology 2007; 212:57-70; PMID:17270710; DOI:10.1016/j.imbio.2006.08.005.
80. Vázquez AM, Alfonso M, Lanne B, Karlsson KA, Carr A, Barroso O, et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 1995; 14:551-6; PMID:8770642; DOI:10.1089/hyb.1995.14. 551.
81. Moreno E, Lanne B, Vazquez AM, Kawashima I, Tai T, Fernandez LE, et al. Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. Glycobiology 1998; 8:695-705; PMID:9621110; DOI:10.1093/glycob/ 8.7.695.
82. López-Requena A, Mateo de Acosta C, Perez A, Valle A, Lombardero J, Sosa K, et al. Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic mAbs: immunodominance of their variable regions. Hybrid Hybridomics 2003; 22:235-43; PMID:14511569; DOI:10.1089/153685903322328965.
83. Perez A, Lombardero J, Mateo C, Mustelier G, Alfonso M, Vazquez AM, et al. Immunogenetic analysis of variable regions encoding AB1 and gamma-type AB2 antibodies from the NeuGc-containing ganglioside family. Hybridoma 2001; 20:211-21; PMID:11604106; DOI:10.1089/027245701753179785.
84. Fernández-Marrero Y, Hernandez T, Roque-Navarro L, Talavera A, Moreno E, Grinan T, et al. Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody. Mol Immunol 2011; 48:1059-67; PMID:21306777; DOI:10.1016/j.molimm.2011.01.008.
85. Guth AM, Zhang X, Smith D, Detanico T, Wysocki LJ. Chromatin specificity of anti-double-stranded DNA antibodies and a role for Arg residues in the third complementarity- determining region of the heavy chain. J Immunol 2003; 171:6260-6; PMID:14634143.
86. Giles I, Lambrianides N, Latchman D, Chen P, Chukwuocha R, Isenberg D, et al. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. Arthritis Res Ther 2005; 7:47-56; PMID:15642142; DOI:10.1186/ar1449.
87. Giles I, Lambrianides N, Pattni N, Faulkes D, Latchman D, Chen P, et al. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol 2006; 177:1729-36; PMID:16849482.
88. López-Requena A, De Acosta CM, Moreno E, Gonzalez M, Puchades Y, Talavera A, et al. Gangliosides, Ab1 and Ab2 antibodies I. Towards a molecular dissection of an idiotype-anti-idiotype system. Mol Immunol 2007; 44:423-33; PMID:16581129.
89. Talavera A, Eriksson A, Okvist M, Lopez-Requena A, Fernandez-Marrero Y, Perez R, et al. Crystal structure of an anti-ganglioside antibody and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol 2009; 46:3466-75; PMID:19748674; DOI:10.1016/j.molimm. 2009.07.032.
90. Vázquez AM, Perez A, Hernandez AM, Macias A, Alfonso M, Bombino G, et al. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 1998; 17:527-34; PMID:9890708; DOI:10.1089/hyb.1998.17.527.
91. Hernández AM, Rodriguez N, Gonzalez JE, Reyes E, Rondon T, Grinan T, et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol 2011; 186:3735-44; PMID:21300821; DOI:10.4049/jimmunol.1000609.
92. Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S, et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 2005; 280:41940-52; PMID:16234248; DOI:10.1074/jbc.M503621200.
93. Wu GS, Kim K, el-Deiry WS. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 2000; 465:143-51; PMID:10810622; DOI:10.1007/0-306-46817-4-13.
94. Gu Z, Yamashiro J, Kono E, Reiter RE. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 2005; 65:9495-500; PMID:16230414; DOI:10.1158/0008-5472.CAN-05-2086.
95. Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006; 20:272-9; PMID:16341049; DOI:10.1038/sj.leu.2404014.
96. Garrido G, Rabasa A, Sánchez B, López MV, Blanco R, López A, et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 2011; In press; PMID: 21984704; DOI: 10.4049/jimmunol. 1003477.